Today: 1 July 2026
Browse Category

NYSE:JNJ 8 February 2026 - 15 June 2026

Amazon Shares Slip After $17.5 Billion AI Loan Draws Focus to AMZN Cash Flow

Amazon takes number one spot on 2026 Fortune 500; regional shifts seen

Amazon has taken the No. 1 spot on the 2026 Fortune 500, Fortune said, unseating Walmart after 13 years at the top. The change put Amazon ahead for the first time in more than a decade and drove shifts in regional tallies for Pennsylvania, New Jersey and New England. Fortune’s 72nd annual list put the collective revenue at $21.0 trillion, with profits at $2.1 trillion and a workforce of 30.5 million worldwide. Erie Insurance traded higher. The insurer out of Pennsylvania moved up 15 spots to No. 308 on the 2026 Fortune 500, now with 23 straight years on the list. Fortune listed Erie Insurance at $14.62 billion in revenue and $1.13 billion in profit. The company said its current streak on the Fortune 500 goes back to 2003.
15 June 2026
···········
3 Dividend Stocks for the Long Haul in 2026

3 Dividend Stocks for the Long Haul in 2026

Defensive dividend stocks joined Friday’s rally as the S&P 500 rose 0.5% and the Dow finished up 0.7%. Johnson & Johnson traded at $240.87, Coca-Cola at $82.62, and Procter & Gamble at $149.61 at the close, Friday figures show. J&J’s P/E ratio is around 27.9, Coca-Cola’s 26.0, and P&G’s 21.9. Johnson & Johnson is sticking to its role as a healthcare pick for dividend-focused investors who don’t want consumer staples exposure. In April the company bumped its quarterly dividend by 3.1%, putting the annual payout at $5.36 per share. That’s 64 straight years of hikes. At Friday’s close, the yield works out to about 2.2%. J&J is pointing to a stronger 2026 outlook after Q1 sales jumped 9.9% to $24.1 billion and adjusted EPS hit $2.70. It flagged its planned $1 billion Firefly Bio buyout as another step for its oncology pipeline.
14 June 2026
···
Johnson & Johnson Shares Hold Up in Market Selloff — Looking at What May Shift JNJ Next Week

Johnson & Johnson Shares Hold Up in Market Selloff — Looking at What May Shift JNJ Next Week

Johnson & Johnson heads into the week with less clutter than much of the Street. Shares gained 2.0% to $232.77 on Friday, while most stocks sank. The last regular session wrapped up at 4:00 p.m. New York time on June 5. With markets closed Saturday, that $232.77 is the number investors see. Johnson & Johnson went against the market on Friday. The S&P 500 lost 2.6% and the Nasdaq slid 4.2% as rate fears pressured growth stocks, according to Investor’s Business Daily. J&J gained as investors rotated into healthcare and defensive names — shares seen as safer from economic swings.
6 June 2026
·
Johnson & Johnson Shares Drop Friday, Week Ahead in Focus

Johnson & Johnson stock trades higher ahead of Memorial Day: Eyes on next moves for JNJ

Johnson & Johnson shares gained 1.13% on Friday, closing at $234.34, and ended the week up about 3.4%. That put the Dow name ahead of the S&P 500’s weekly move going into the U.S. Memorial Day holiday. Big healthcare stocks are drawing buyers as investors look past tech and the market rally picks up steam. The S&P 500 logged an eighth consecutive weekly gain. The Dow Jones Industrial Average finished Friday at a new record high.
23 May 2026
·
Kenvue Stock Watch Just Got Fresh Signals Before Monday — Here’s Why KVUE Traders Are Paying Attention

Kenvue Stock Watch Just Got Fresh Signals Before Monday — Here’s Why KVUE Traders Are Paying Attention

Stock Traders Daily published a new AI-generated trading note on Kenvue Inc. on Sunday, setting fresh price levels for the Tylenol maker before U.S. shares reopen on Monday. The note put KVUE in a neutral near-term and mid-term setup, while calling its longer-term signal weak, against a current-price marker of $17.11. The timing matters because the stock is not trading now. Kenvue last changed hands at $17.11 on Friday, down about 0.5%, and the New York Stock Exchange’s core session runs from 9:30 a.m. to 4 p.m. Eastern time on trading days.
18 May 2026
···
Johnson & Johnson Shares Drop Friday, Week Ahead in Focus

Johnson & Johnson Shares Drop Friday, Week Ahead in Focus

Johnson & Johnson stock starts the week above Friday’s lows. The drug and medical-device company fell 1.77% to $226.71 on Friday as markets dropped, but the shares ended last week with a gain. J&J had run up earlier in the week, closing at $221.43 Monday, $224.26 Tuesday, $230.42 Wednesday and $230.80 Thursday, then lost ground Friday, Investing.com data show. Despite the drop, it ended about 2.4% over its May 8 close.
16 May 2026
·
Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

The Dow Jones Industrial Average managed a modest gain Tuesday, bucking declines in the S&P 500 and a steeper slide for the Nasdaq as traders moved out of AI stocks and into more stable blue chips. According to LSEG figures cited by Reuters, the Dow closed up 100.62 points, or 0.20%, at 49,268.41. The S&P 500 slipped 0.64%, with the Nasdaq down 1.24%. The split stands out: the selloff’s hit isn’t spread evenly. Because the Dow is price-weighted, stocks with bigger price tags have an outsized impact. Coca-Cola and Johnson & Johnson, both trading higher, managed to cushion the blow—together, they tacked on roughly 48 points to the Dow, according to MarketWatch.
28 April 2026
·······
Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

NEW BRUNSWICK, N.J., April 14, 2026, 09:05 EDT Johnson & Johnson topped Wall Street’s Q1 expectations on Tuesday, helped by surging sales from the cancer therapy Darzalex and the psoriasis drug Tremfya. Those gains made up for a sharp decline in Stelara, which used to be a major driver. Revenue climbed 9.9% to $24.1 billion, beating forecasts of $23.6 billion. Adjusted earnings reached $2.70 a share, also above the $2.66 consensus. The company lifted its 2026 outlook.
14 April 2026
···
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

BEERSE, Belgium, March 10, 2026, 18:42 Johnson & Johnson on Tuesday said it’s filed with the European Medicines Agency to expand Tecvayli’s EU label, aiming to allow the therapy as a single agent for adults with relapsed or refractory multiple myeloma who’ve already had at least one prior treatment. That would move the drug up in the treatment sequence for the blood cancer, where, according to the company, patients still encounter some of the toughest care gaps.
10 March 2026
···
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

New York, Feb 23, 2026, 10:44 a.m. EST — Regular session underway. Shares of Arcellx surged roughly 78% to $113.92 Monday morning, following news that Gilead Sciences will acquire the cancer therapy maker—pushing the stock close to the buyout price. The takeover puts Arcellx’s valuation as high as $7.8 billion, factoring in a contingent sales-related bonus.
23 February 2026
····
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

New York, Feb 21, 2026, 13:06 EST — The market has shut its doors. Johnson & Johnson is weighing a sale of its DePuy Synthes orthopedics division that could fetch more than $20 billion, according to a source familiar with the situation, speaking to Reuters on Thursday. The company hasn’t commented yet. This potential sale marks a pivot from J&J’s previously outlined plan to spin off DePuy Synthes over the next 18 to 24 months. CFO Joe Wolk previously indicated no major updates would come before mid-2026. DePuy pulled in $9.3 billion in sales for 2025 and has faced thousands of hip implant lawsuits, Reuters noted.
21 February 2026
··
1 2 3 … 9

Stock Market Today

  • ASX 200 trails global indexes in 2026 as key healthcare names dive
    July 1, 2026, 3:42 AM EDT. The ASX 200 barely managed a gain of less than 2.8% for the 2026 financial year, outpaced by major overseas markets. The rise was negative after inflation. US stocks soared, with the S&P 500 up 20.8%, NASDAQ up 28.7%, and Europe's STOXX 600 climbing 19%. Losses for CSL-off 52%-and Cochlear, down almost 60%, weighed on the Australian market. Bank results were mixed; ANZ gained 16% but Commonwealth Bank and NAB lagged. 4D Medical stood out with strong returns while the rest of the market barely moved.
Go toTop